Symptoms and causes


Multiple sclerosis signs and symptoms may differ greatly from person to person and over the course of the disease depending on the location of affected nerve fibers. They may include:

  • Numbness or weakness in one or more limbs that typically occurs on one side of your body at a time, or the legs and trunk
  • Partial or complete loss of vision, usually in one eye at a time, often with pain during eye movement
  • Prolonged double vision
  • Tingling or pain in parts of your body
  • Electric-shock sensations that occur with certain neck movements, especially bending the neck forward (Lhermitte sign)
  • Tremor, lack of coordination or unsteady gait
  • Slurred speech
  • Fatigue
  • Dizziness
  • Problems with bowel and bladder function

When to see a doctor

See a doctor if you experience any of the above symptoms for unknown reasons.

Disease course

Most people with MS have a relapsing-remitting disease course. They experience periods of new symptoms or relapses that develop over days or weeks and usually improve partially or completely. These relapses are followed by quiet periods of disease remission that can last months or even years.

Small increases in body temperature can temporarily worsen signs and symptoms of MS, but these aren't considered disease relapses.

About 60 to 70 percent of people with relapsing-remitting MS eventually develop a steady progression of symptoms, with or without periods of remission, known as secondary-progressive MS.

The worsening of symptoms usually includes problems with mobility and gait. The rate of disease progression varies greatly among people with secondary-progressive MS.

Some people with MS experience a gradual onset and steady progression of signs and symptoms without any relapses. This is known as primary-progressive MS.


The cause of multiple sclerosis is unknown. It's considered an autoimmune disease in which the body's immune system attacks its own tissues. In the case of MS, this immune system malfunction destroys myelin (the fatty substance that coats and protects nerve fibers in the brain and spinal cord).

Myelin can be compared to the insulation coating on electrical wires. When the protective myelin is damaged and nerve fiber is exposed, the messages that travel along that nerve may be slowed or blocked. The nerve may also become damaged itself.

It isn't clear why MS develops in some people and not others. A combination of genetics and environmental factors appears to be responsible.

Risk factors

These factors may increase your risk of developing multiple sclerosis:

  • Age. MS can occur at any age, but most commonly affects people between the ages of 15 and 60.
  • Sex. Women are about twice as likely as men are to develop MS.
  • Family history. If one of your parents or siblings has had MS, you are at higher risk of developing the disease.
  • Certain infections. A variety of viruses have been linked to MS, including Epstein-Barr, the virus that causes infectious mononucleosis.
  • Race. White people, particularly those of Northern European descent, are at highest risk of developing MS. People of Asian, African or Native American descent have the lowest risk.
  • Climate. MS is far more common in countries with temperate climates, including Canada, the northern United States, New Zealand, southeastern Australia and Europe.
  • Certain autoimmune diseases. You have a slightly higher risk of developing MS if you have thyroid disease, type 1 diabetes or inflammatory bowel disease.
  • Smoking. Smokers who experience an initial event of symptoms that may signal MS are more likely than nonsmokers to develop a second event that confirms relapsing-remitting MS.


People with multiple sclerosis also may develop:

  • Muscle stiffness or spasms
  • Paralysis, typically in the legs
  • Problems with bladder, bowel or sexual function
  • Mental changes, such as forgetfulness or mood swings
  • Depression
  • Epilepsy
Oct. 01, 2015
  1. AskMayoExpert. What is multiple sclerosis? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  2. Daroff RB, et al. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2012. Accessed Dec. 16, 2014.
  3. Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. Accessed April 4, 2014.
  4. Olek MJ. Epidemiology and clinical features of multiple sclerosis in adults. Accessed April 4, 2014.
  5. Wingerchuk DM (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. May 13, 2014.
  6. Kantarci O. Treatment of primary progressive multiple sclerosis. Seminars in Neurology. 2013;33:74.
  7. Keegan BM. Therapeutic decision making in a new drug era in multiple sclerosis. Seminars in Neurology. 2013;33:5.
  8. Goldman L, et al. Goldman's Cecil Medicine. 24th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. Accessed April 4, 2014.
  9. Lotze TE. Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis. Accessed April 5, 2014.
  10. Kantarci OH, et al. Novel immunomodulatory approaches for the management of multiple sclerosis. Clinical Pharmacology & Therapeutics. 2014;95:32.
  11. Olek MJ. Treatment of relapsing-remitting multiple sclerosis in adults. Accessed Dec. 16, 2014.
  12. Olek MJ. Treatment of acute exacerbations of multiple sclerosis in adults. Accessed April 4, 2014.
  13. Wingerchuk DM. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clinic Proceedings. 2014;89:225.
  14. Pizzorno JE, et al. Textbook of Natural Medicine. 4th ed. St. Louis, Mo.: Churchill Livingstone Elsevier; 2013. Accessed April 4, 2014.
  15. Olek MJ. Diagnosis of multiple sclerosis in adults. Accessed Jan. 2, 2015.
  16. Polman, C, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology. 2011;69:292.
  17. Patient information: Multiple sclerosis. Accessed Jan. 2, 2015.
  18. Olek MJ. Symptom management of multiple sclerosis in adults. Accessed Jan. 2, 2015.
  19. Yadav Y, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology. 2014;82:1083.
  20. Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Jan. 20, 2015.
  21. National MS Society. Network of Pediatric MS Centers. Accessed Feb. 10, 2015.
  22. Rodriguez M. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993;43:1100.
  23. Deb C. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLOS One. Aug. 30, 2010.